Lixisenatide shows no effect on arterial stiffness in type 2 diabetes with chronic kidney disease

A single-center, proof-of-concept randomized controlled trial investigated the effect of the GLP-1 receptor agonist lixisenatide on arterial stiffness in people with type 2 diabetes and chronic kidney disease. The study enrolled 101 participants who were randomized, with 90 eligible for final analyses (lixisenatide n=47, placebo n=43). The trial was conducted over a 24-week follow-up period, focusing on this high-risk population where arterial stiffness is a known contributor to cardiovascular morbidity.

Participants received either 24 weeks of treatment with lixisenatide or a matching placebo. The specific dosing regimen and titration protocol for lixisenatide were not reported in the provided data. Similarly, details about the placebo formulation and administration schedule were not specified. Both groups were followed for the full 24-week duration to assess the primary outcome.

The primary outcome was aortic pulse wave velocity (Ao-PWV), a surrogate marker of arterial stiffness. The study found no significant change from baseline in Ao-PWV with lixisenatide treatment compared to placebo. The final mean Ao-PWV was 9.65 m/s in the lixisenatide group and 9.96 m/s in the placebo group. The between-group difference was not statistically significant (p=0.38). The 95% confidence interval for the lixisenatide group was (9.17, 10.13) m/s, and for the placebo group was (9.45, 10.46) m/s. No effect size was reported for this primary outcome.

Key secondary outcomes included cardio-renal risk biomarkers (specifically albuminuria and Klotho levels) and glycemic control measured by HbA1c. For the cardio-renal biomarkers, the study reported no significant changes observed with lixisenatide treatment compared to placebo. Absolute numbers and effect sizes for these biomarkers were not reported. However, for HbA1c, the study found a decrease with lixisenatide as compared to placebo, indicating a beneficial effect on glycemic control. Specific absolute numbers, magnitude of reduction, or p-values for the HbA1c outcome were not provided in the available data.

Safety and tolerability findings were not reported in the provided information. Details about adverse events, serious adverse events, discontinuation rates, and overall tolerability of lixisenatide in this population with type 2 diabetes and chronic kidney disease were not available from the study summary.

These results contribute to the ongoing investigation of GLP-1 receptor agonists in cardiovascular and renal protection. While some GLP-1 RAs have demonstrated cardiovascular outcome benefits in large trials, this study specifically examining lixisenatide's effect on arterial stiffness—a surrogate marker—showed no significant impact. The discordance between the lack of effect on Ao-PWV and the observed HbA1c reduction highlights the complexity of GLP-1 RA mechanisms and their translation to vascular benefits. The study authors note that these findings do not explain the discordance in cardiovascular outcome trials observed with different GLP-1 receptor agonists.

The study has several methodological limitations. As a proof-of-concept study conducted at a single center, its generalizability is limited. The sample size of 90 participants eligible for analysis may have been underpowered to detect smaller but potentially clinically meaningful differences in Ao-PWV. The study measured only surrogate markers (Ao-PWV and biomarkers) rather than clinical cardiovascular outcomes such as myocardial infarction, stroke, or cardiovascular death. Additionally, key details about dosing, safety, and specific biomarker results were not reported in the available summary.

Clinical implications from this study suggest that lixisenatide may not improve arterial stiffness as measured by Ao-PWV in people with type 2 diabetes and chronic kidney disease, despite its expected glycemic benefits. Clinicians should not expect vascular improvements from lixisenatide based on this surrogate marker, though the drug may still be appropriate for glycemic management in this population. The findings highlight that different GLP-1 receptor agonists may have varying effects on cardiovascular parameters beyond glucose control.

Several important questions remain unanswered. The study does not address whether longer treatment duration might yield different effects on arterial stiffness. The mechanism behind the discordance between HbA1c improvement and lack of Ao-PWV change requires further investigation. Most importantly, the relationship between Ao-PWV changes (or lack thereof) and actual clinical cardiovascular outcomes with lixisenatide treatment remains unknown. Future studies should examine clinical cardiovascular endpoints in this population and investigate whether other GLP-1 receptor agonists might have different effects on arterial stiffness parameters.